Status:
COMPLETED
A 3-year, Prospective, Non-interventional, Multicenter Registry in Sickle Cell Disease (SCD) Patients
Lead Sponsor:
Novartis
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
2+ years
Brief Summary
A long term observational study in sickle cell disease will enhance the understanding of the disease patterns, current transfusion practices, treatments and outcomes in sickle cell disease.
Eligibility Criteria
Inclusion
- Male or female patients with HbSS, HbS/beta-thalassemia and HbSC
- Age \> 2 years old.
- Written informed consent by the patient or legal guardians, and pediatric assent where indicated.
Exclusion
- Patients with Sickle Cell trait (HbAS) are not eligible for the study
- Patient or legal guardians unable or unwilling to give consent, or pediatric assent where indicated.
Key Trial Info
Start Date :
January 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2014
Estimated Enrollment :
498 Patients enrolled
Trial Details
Trial ID
NCT01220115
Start Date
January 1 2010
End Date
September 1 2014
Last Update
December 9 2019
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Hematology Oncology Services of Arkansas
Little Rock, Arkansas, United States, 72205
2
Children's Hospital Oakland (CHO)
Oakland, California, United States, 94609
3
Children's Hospital of Orange County Sickle Cell Disease Center
Orange, California, United States, 92668
4
Rady Children's Hopsital / UC San Diego University Hospital Sickle Cell Disease Center
San Diego, California, United States, 92123